Allan Wailoo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6856937/publications.pdf

Version: 2024-02-01

331670 434195 1,147 32 21 31 citations h-index g-index papers 32 32 32 1861 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study. Lancet, The, 2017, 389, 538-546.	13.7	217
2	EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. Value in Health, 2018, 21, 49-56.	0.3	71
3	The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis. Rheumatology, 2013, 52, 944-950.	1.9	63
4	It ain't what you do, it's the way that you do it: Characteristics of procedural justice and their importance in social decision-making. Journal of Economic Behavior and Organization, 2007, 64, 157-170.	2.0	55
5	Weighting Must Wait. Pharmacoeconomics, 2009, 27, 983-989.	3.3	55
6	A Comparison of Direct and Indirect Methods for the Estimation of Health Utilities from Clinical Outcomes. Medical Decision Making, 2014, 34, 919-930.	2.4	52
7	The Cost-Effectiveness of Antibiotic Prophylaxis for Patients at Risk of Infective Endocarditis. Circulation, 2016, 134, 1568-1578.	1.6	51
8	Utilities versus Rights to Publicly Provided Goods: Arguments and Evidence from Health Care Rationing. Economica, 2000, 67, 543-577.	1.6	50
9	Societal Preferences for Distributive Justice in the Allocation of Health Care Resources. Medical Decision Making, 2015, 35, 94-105.	2.4	47
10	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2017, 21, 1-258.	2.8	37
11	The nature of procedural preferences for health-care rationing decisions. Social Science and Medicine, 2005, 60, 223-236.	3.8	35
12	Modelling the relationship between the WOMAC osteoarthritis index and EQ-5D. Health and Quality of Life Outcomes, 2014, 12, 37.	2.4	34
13	Fitting Adjusted Limited Dependent Variable Mixture Models to EQ-5D. The Stata Journal, 2015, 15, 737-750.	2.2	34
14	MRI in the diagnosis of fetal developmental brain abnormalities: the MERIDIAN diagnostic accuracy study. Health Technology Assessment, 2019, 23, 1-144.	2.8	34
15	The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review. BMJ Open, 2014, 4, e005244-e005244.	1.9	31
16	Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project. Heart, 2010, 96, 668-672.	2.9	30
17	Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods. Value in Health, 2015, 18, 425-431.	0.3	30
18	The EQ-5D-5L Value Set for England: Findings of a Quality Assurance Program. Value in Health, 2020, 23, 642-648.	0.3	29

#	Article	IF	CITATIONS
19	A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents. Value in Health, 2020, 23, 907-917.	0.3	25
20	The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals. Pharmacoeconomics, 2019, 37, 75-84.	3.3	22
21	Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations. Pharmacoeconomics, 2013, 31, 643-652.	3.3	21
22	Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology, 2014, 53, 1773-1777.	1.9	21
23	The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation. Health Technology Assessment, 2018, 22, 1-204.	2.8	21
24	Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods. Health Technology Assessment, 2020, 24, 1-68.	2.8	19
25	What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis. Health Technology Assessment, 2018, 22, 1-258.	2.8	17
26	Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. Trials, 2017, 18, 591.	1.6	14
27	An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis. Value in Health, 2021, 24, 568-574.	0.3	11
28	The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial. Seminars in Arthritis and Rheumatism, 2020, 50, 1182-1190.	3.4	10
29	Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. SN Comprehensive Clinical Medicine, 2021, 3, 838-854.	0.6	8
30	Measuring quality of life of patients with axial spondyloarthritis for economic evaluation. RMD Open, 2022, 8, e001955.	3.8	2
31	Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. Programme Grants for Applied Research, 2021, 9, 1-186.	1.0	1
32	Variations in primary care prescribing: lessons to be learnt for GP commissioners. Primary Health Care Research and Development, 2014, 15, 111-116.	1.2	0